ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

Ontak Approved For Lymphoma

October 31, 2008

Horvitz Wins BMS Award In Neuroscience; Group Room To Discuss Congressional Issues.

February 22, 2002

ACCC Established FCCC Special Interest Group

April 11, 1986

ACS Clinical Awards Available For 1996

March 31, 1995

Hyperthermia, Radiation Enhancement, New Drugs Offer More Therapy Advances, ASCO Members Hear

April 7, 1978

Eight Years Later:In A Change of Heart, LCA Endorses NLST

April 18, 2014